141 related articles for article (PubMed ID: 11839441)
1. Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes.
Ruiz-Balaguer N; Nacher A; Casabo VG; Merino Sanjuan M
Int J Pharm; 2002 Mar; 234(1-2):101-11. PubMed ID: 11839441
[TBL] [Abstract][Full Text] [Related]
2. Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats.
Ruiz-Balaguer N; Nacher A; Casabo VG; Merino M
Antimicrob Agents Chemother; 1997 Feb; 41(2):445-8. PubMed ID: 9021205
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective absorption and hydrolysis of cefuroxime axetil diastereomers using the Caco-2 cell monolayer model.
Barrett MA; Lawrence MJ; Hutt AJ; Lansley AB
Eur J Drug Metab Pharmacokinet; 1997; 22(4):409-13. PubMed ID: 9512942
[TBL] [Abstract][Full Text] [Related]
4. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells.
Dantzig AH; Duckworth DC; Tabas LB
Biochim Biophys Acta; 1994 Apr; 1191(1):7-13. PubMed ID: 8155686
[TBL] [Abstract][Full Text] [Related]
5. Esterase activity toward the diastereomers of cefuroxime axetil in the rat and dog.
Mosher GL; McBee J; Shaw DB
Pharm Res; 1992 May; 9(5):687-9. PubMed ID: 1608904
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat.
Ruiz-Carretero P; Nacher A; Merino-Sanjuan M; Casabo VG
Int J Pharm; 2000 Jul; 202(1-2):89-96. PubMed ID: 10915930
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime.
Ruiz-Carretero P; Merino-Sanjuán M; Nácher A; Casabó VG
Eur J Pharm Sci; 2004 Feb; 21(2-3):217-23. PubMed ID: 14757493
[TBL] [Abstract][Full Text] [Related]
8. [Stepwise therapy of community-acquired pneumonia. Results of cefuroxime and cefuroxime axetil study].
Iakovlev SV; Suvorova MP; Dvoretskiĭ LI; Vlasenko NA; Shakhova TV
Antibiot Khimioter; 1998; 43(6):7-11. PubMed ID: 9644527
[TBL] [Abstract][Full Text] [Related]
9. Penetration of oral cefuroxime axetil into the human aqueous humor.
Ghia M; Lotti R; Traverso C; Mattioli F; Martelli A
Ophthalmologica; 1997; 211(4):229-31. PubMed ID: 9216013
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cefuroxime axetil and cefadroxil suspensions for treatment of pediatric skin infections.
Jacobs RF; Brown WD; Chartrand S; Darden P; Drehobl MA; Yetman R; Ossi MJ
Antimicrob Agents Chemother; 1992 Aug; 36(8):1614-8. PubMed ID: 1416842
[TBL] [Abstract][Full Text] [Related]
11. Model simulation of a single oral dose of cefuroxime axetil and the related in-vitro kill kinetics against four bacterial species.
Silley P; Monsey D; Harris AM
J Antimicrob Chemother; 1990 Jan; 25(1):83-90. PubMed ID: 2180892
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and tolerability of cefuroxime-axetil in infections of the upper respiratory tract. Comparative study with cefadroxil].
Dupuis G; Ebbo D; Evennou A; Pappo M
Rev Laryngol Otol Rhinol (Bord); 1989; 110(1):123-6. PubMed ID: 2491707
[TBL] [Abstract][Full Text] [Related]
13. Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects.
Mendes GD; Borges A; de Cássia Val L; Patni AK; Reyar S; Monif T; Sereno D; Orellana AM; De Nucci G
Arzneimittelforschung; 2010; 60(2):101-5. PubMed ID: 20329659
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of cefuroxime axetil formulations.
Donn KH; James NC; Powell JR
J Pharm Sci; 1994 Jun; 83(6):842-4. PubMed ID: 9120818
[TBL] [Abstract][Full Text] [Related]
15. The relationship of diastereomer hydrolysis kinetics to shelf-life predictions for cefuroxime axetil.
Nguyen NA
Pharm Res; 1991 Jul; 8(7):893-8. PubMed ID: 1924141
[TBL] [Abstract][Full Text] [Related]
16. Clinical comparison of cefuroxime axetil, cephalexin and cefadroxil in the treatment of patients with primary infections of the skin or skin structures.
Gooch WM; Kaminester L; Cole GW; Binder R; Morman MR; Swinehart JM; Wisniewski M; Yilmaz HM; Collins JJ
Dermatologica; 1991; 183(1):36-43. PubMed ID: 1769413
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the penetration of cefuroxime axetil into human paranasal sinus tissue.
Sudderick RM; Lund VJ; Thomson JP; McCombe A; Mackay IS
Rhinology; 1992 Mar; 30(1):11-6. PubMed ID: 1579807
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.
James NC; Donn KH; Collins JJ; Davis IM; Lloyd TL; Hart RW; Powell JR
Antimicrob Agents Chemother; 1991 Sep; 35(9):1860-3. PubMed ID: 1952858
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics in the elderly with reference to the oral prodrug cefuroxime axetil.
Kelsey MC
J Chemother; 1989 Jul; 1(4 Suppl):517-8. PubMed ID: 16312511
[No Abstract] [Full Text] [Related]
20. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
Perry CM; Brogden RN
Drugs; 1996 Jul; 52(1):125-58. PubMed ID: 8799689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
